Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Biosci Biotechnol Biochem ; 87(2): 197-207, 2023 Jan 24.
Artigo em Inglês | MEDLINE | ID: mdl-36521839

RESUMO

The protamine-derived peptide arginine-proline-arginine (RPR) can ameliorate lifestyle-related diseases such as obesity and hypercholesterolemia. Thus, we hypothesized that the hypolipidemic activity of RPR could attenuate events leading to non-alcoholic fatty liver disease. Addition of 2 m m oleic acid (OA) to the culture medium induced fatty liver conditions in HepG2 cells. The OA + RPR group showed significantly decreased cellular or medium triglyceride (TG) level compared with the OA group. Stearoyl-CoA desaturase-1 (SCD1) or sterol regulatory element-binding protein 1 (SREBP1) protein level was significantly lower in the OA + RPR group than in the OA group. In the R + P + R amino acid mixture-treated group, the TG level was not significantly different from that in the OA-treated group. The OA + RP- or OA + PR-treated groups showed significantly decreased cellular TG level compared with the OA group. Moreover, the effect of RPR disappeared when the peptide transporter 1 (PepT1) was knocked down with a siRNA. Collectively, our results demonstrated that RPR effectively ameliorated hepatic steatosis in HepG2 cells via the PepT1 pathway.


Assuntos
Lipogênese , Hepatopatia Gordurosa não Alcoólica , Humanos , Ácido Oleico/farmacologia , Células Hep G2 , Transportador 1 de Peptídeos/metabolismo , Protaminas , Hepatopatia Gordurosa não Alcoólica/metabolismo , Peptídeos/metabolismo , Prolina/metabolismo
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...